Overexpression of cyclooxygenase-2 in rat oral cancers and prevention of oral carcinogenesis in rats by selective and nonselective COX inhibitors

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 73-81

  McCormick, David L ^a   Phillips, Jonathan M ^a   Horn, Thomas L ^a   Johnson, William D ^a   Steele, Vernon E ^b   Lubet, Ronald A ^b  

^a IIT RESEARCH INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DRINKING WATER; NAPROXEN; PIROXICAM; ZILEUTON; DRUG DERIVATIVE; HYDROXYUREA; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; FISCHER 344 RAT; GASTROINTESTINAL TOXICITY; GENE OVEREXPRESSION; MALE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; RAT; SQUAMOUS CELL CARCINOMA; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION; MOUTH TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; GENE EXPRESSION; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MALE; MOUTH NEOPLASMS; NAPROXEN; PIROXICAM; PYRAZOLES; RATS; RATS, INBRED F344; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFONAMIDES; UP-REGULATION;

EID: 77649229334     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0151     Document Type: Article

References (34)

1. Gerson SJ. Oral cancer. Crit Rev Oral Biol Med 1990;1:153-66.
2. Shantz SP, Ostroff JS. Novel approaches to the prevention of head and neck cancer. Proc Soc Exptl Biol Med 1998;216:275-82.
3. Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008;9:667-75.
4. Petersen PE. Oral cancer prevention and control-the approach of the World Health Organization. Oral Oncol 2008;45:454-60.
5. Walker DM, Boey G, McDonald LA. The pathology of oral cancer. Pathology 2003;35:376-83.
6. Swango PA. Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. J Public Health Dent 1996;56:309-18.
7. Polednak AP. Trends in incidence rates of tobacco-related cancer, selected areas, SEER Program, United States, 1992-2004. Prev Chronic Dis 2009;6:A16.
8. American Cancer Society. Cancer Facts and Figures 2009. Atlanta: American Cancer Society; 2009.
9. McGettigan P, Henry D. Current problems with non-specific COX inhibitors. Curr Pharm Des 2000;6:1693-724.
10. Jones A. Over-the-counter analgesics: a toxicology perspective. Am J Ther 2002;9:245-57.
11. Thun MJ, Henly SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;91:252-66.
12. Rao CV, Reddy BS. NSAIDs and chemoprevention. Curr Cancer Drug Targets 2004;4:29-42.
13. Dubé C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U S. Preventive Services Task Force. Ann Intern Med 2007;146:365-75.
14. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analytis of the randomized trials. J Natl Cancer Inst 2009;101:256-66.
15. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
16. Slatore CG, Au DH, Littman AJ, Satia JA, White E. Association of nonsteroidal anti-inflammatory drugs with lung cancer: results from a large cohort study. Cancer Epidemiol Biomarkers Prev 2009;18:1203-7.
17. Clouser MC, Roe DJ, Foote JA, Harris RB. Effect of non-steroidal anti-inflammatory drugs on non-melanoma skin cancer incidence in the SKICAP-AK trial. Pharmacoepidemiol Drug Saf 2009;18:276-83.
18. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 2000;343:1520-8.
19. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:639-40.
20. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
21. Solomon DH. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum 2005;52:1968-78.
22. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
23. Kerr DJ, Dunn JA, Langman MJ, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360-9.
24. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib trial. Cancer Prev Res 2009;2:310-21.
25. Li N, Sood S, Wang S, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005;11:2089-96.
26. McCormick DL, Moon RC. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br J Cancer 1983;48:859-61.
27. McCormick DL, Madigan M, Moon RC. Modulation of rat mammary carcinogenesis by indomethacin. Cancer Res 1985;45:1803-6.
28. McCormick DL, Spicer AM. Nordihydroguaiaretic acid suppression of rat mammary carcinogenesis induced by N-methyl-N-nitrosourea. Cancer Lett 1987;37:139-46.
29. Rao KVN, McCormick DL, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ. Differential activity of aspirin, ketoprofen, and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435-8.
30. Sudbo J, Ristimäki A, Sondresen JE, et al. Cyclooxygenase-2 (COX-2) expression in high-risk premalignant oral lesions. Oral Oncol 2007;43:420.
31. Pandey M, Prakash O, Santhi WS, Soumithran CS, Pillai RM. Over-expression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. Int J Oral Maxillofac Surg 2008;37:379-83.
32. Papadimitrakopoulu VA, William WN, Jr., Dannenberg AJ, et al. Pilot radomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14:2095-101.
33. Wilder-Smith CH, Jonzon B, Fornstedt-Wallin B, et al. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastro-intestinal tract mucosal injury in healthy subjects. Scand J Gastroenterol 2006;41:264-73.
34. Fiorucci S, Antonelli E. NO-NSAIDs: from inflammatory mediators to clinical readouts. Inflamm Allergy Drug Targets 2006;5:131.